Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
acetyl-CoA + 2,5-dimethoxyphenylethylamine
CoA + ?
24% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(2,3-dichlorophenyl)-ethylamine
CoA + N-acetyl-2-(2,3-dichlorophenyl)-ethylamine
78% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(2-chlorophenyl)-ethylamine
CoA + N-acetyl-2-(2-chlorophenyl)-ethylamine
130% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(3,4-dihydroxyphenyl)-ethylamine
CoA + N-acetyl-2-(3,4-dihydroxyphenyl)-ethylamine
7% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(3,4-dimethoxyphenyl)-ethylamine
CoA + N-acetyl-2-(3,4-dimethoxyphenyl)-ethylamine
4.4% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(3-chlorophenyl)-ethylamine
CoA + N-acetyl-2-(3-chlorophenyl)-ethylamine
67% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(3-fluorophenyl)-ethylamine
CoA + N-acetyl-2-(3-fluorophenyl)-ethylamine
65% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(4-bromophenyl)-ethylamine
CoA + N-acetyl-2-(4-bromophenyl)-ethylamine
48% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(4-chlorophenyl)ethylamine
CoA + N-acetyl-2-(4-chlorophenyl)ethylamine
68% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(4-fluorophenyl)-ethylamine
CoA + N-acetyl-2-(4-fluorophenyl)-ethylamine
116% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(p-fluorophenyl)-ethylamine
CoA + N-acetyl-2-(p-fluorophenyl)-ethylamine
56% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(p-nitrophenyl)-ethylamine
CoA + N-acetyl-2-(p-nitrophenyl)-ethylamine
9% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-(p-tolyl)-ethylamine
CoA + N-acetyl-2-(p-tolyl)-ethylamine
60% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-fluorophenylethylamine
CoA + ?
69% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-methoxyphenylethylamine
CoA + N-acetyl-2-methoxyphenylethylamine
52% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 2-phenylethylamine
CoA + N-acetyl-2-phenylethylamine
-
-
-
?
acetyl-CoA + 3-hydroxy-4-methoxyphenethylamine
CoA + ?
1% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 3-hydroxyphenethylamine
CoA + ?
24% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 3-methoxy-2-phenylethylamine
CoA + ?
23% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 3-methoxytyramine
CoA + ?
17% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 4-(2-aminoethyl)-benzenesulfonyl fluoride
CoA + ?
8% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 4-methoxyphenylethylamine
CoA + N-acetyl-4-methoxyphenylethylamine
11% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 6-hydroxydopamine
CoA + ?
51% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + serotonin
CoA + N-acetylserotonin
-
-
-
?
acetyl-CoA + tyramine
CoA + ?
8% of the activity with 2-phenylethylamine
-
-
?
acetyl-CoA + 5-methoxytryptamine
CoA + N-acetyl-5-methoxytryptamine
-
-
-
-
?
acetyl-CoA + beta-phenylethylamine
CoA + N-(2-phenylethyl)-acetaminde
-
-
-
-
?
acetyl-CoA + phenylethylamine
CoA + N-acetyl-phenylethylamine
-
-
-
-
?
acetyl-CoA + serotonin
CoA + N-acetylserotonin
acetyl-CoA + tryptamine
CoA + N-acetyltryptamine
-
-
-
-
?
acetyl-CoA + tyramine
CoA + N-acetyltyramine
-
very poor substrate
-
-
?
additional information
?
-
acetyl-CoA + serotonin
CoA + N-acetylserotonin
-
-
-
-
?
acetyl-CoA + serotonin
CoA + N-acetylserotonin
-
i.e. 5-hydroxytryptamine
-
-
?
acetyl-CoA + serotonin
CoA + N-acetylserotonin
-
rate-limiting in melatonin synthesis
-
-
?
additional information
?
-
no activity with 2-(4-aminophenyl)-ethylamine, 3,4-(dibenzyloxy)phenethylamine, 5-hydroxydopamine, 4-(2-aminoethyl)-benzenesulfonamide or 2-(p-chlorophenoxy)-2-methylpropionic acid
-
-
?
additional information
?
-
-
no activity with 2-(4-aminophenyl)-ethylamine, 3,4-(dibenzyloxy)phenethylamine, 5-hydroxydopamine, 4-(2-aminoethyl)-benzenesulfonamide or 2-(p-chlorophenoxy)-2-methylpropionic acid
-
-
?
additional information
?
-
-
further substrates: selected synthetic amines
-
-
?
additional information
?
-
-
the enzyme catalyzes the rate-limiting step in melatonin synthesis
-
-
?
additional information
?
-
-
enzyme light and diurnal regulation involves phosphorylation on key AANAT Ser and Thr residues, which results in 14-3-3 protein recruitment and changes in catalytic activity and protein stability
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
acetyl-CoA-tryptamine
IC50: 0.00041 mM, GST-AANAT fusion protein
bromoacetyltryptamine
IC50: 0.00143 mM, GST-AANAT fusion protein
S 20251
IC50: 0.002 mM, GST-AANAT fusion protein
S 23823
IC50: 0.005 mM, GST-AANAT fusion protein
-
S 27244
IC50: 0.00072 mM, GST-AANAT fusion protein
S 27481
IC50: 0.00018 mM, GST-AANAT fusion protein
S 28036
IC50: 0.0056 mM,GST-AANAT fusion protein
2-bromo-N-[2-(5-fluoro-1-benzothien-3-yl)ethyl]acetamide
-
IC50: 0.00039 mM
bromoacetyltryptamine
-
IC50: 0.0014 mM
methyl 3-[2-[(bromoacetyl)amino]ethyl]-1-benzothiophene-5-carboxylate
-
IC50: 0.00225 mM
N-[2-(2-benzyl-5-methoxy-benzofuran-3-yl)ethyl]iodoacetamide
-
IC50: 0.0087 mM
N-[2-(2-phenyl-benzo [b]thiophen-3-yl)ethyl]bromoacetamide
-
IC50: 0.001 mM
N-[2-(3-ethyl-7-methoxy-napht-1-yl)ethyl]iodoacetamide
-
IC50: 0.0006 mM
N-[2-(5-bromo-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
-
IC50: 0.00378 mM
N-[2-(5-chloro-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
-
IC50: 0.00018 mM
N-[2-(5-ethyl-1-benzothien-3-yl)ethyl]-2-iodoacetamide
-
IC50: 0.002 mM
N-[2-(5-ethyl-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
-
IC50: 0.00071 mM
N-[2-(5-fluoro-1H-indol-3-yl)ethyl]bromoacetamide
-
IC50: 0.0056 mM
N-[2-(5-hydroxy-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
-
IC50: 0.00018 mM
N-[2-(7-ethyl-1,2,3,4-tetrahydronapht-1-yl)ethyl]iodooacetamide
-
IC50: above 0.1 mM
N-[2-(7-ethyl-napht-1-yl)ethyl]-bromoacetamide
-
IC50: 0.00177 mM
N-[2-(7-hydroxy-naphth-1-yl)ethyl]bromoacetamide
-
IC50: 0.00072 mM
N-[2-(7-methoxy-3-(3-trifluoromethylphenyl)-napht-1-yl)ethyl]iodoacetamide
-
IC50: 0.045 mM
N-[2-(7-methoxy-8-propenyl-napht-1-yl)ethyl]-iodoacetamide
-
IC50: above 0.1 mM
N-[2-(7-methoxy-napht-1-yl)ethyl]bromoacetamide
-
IC50: 0.002 mM
N-[2-(7-propoxy-napht-1-yl)ethyl]iodoacetamide
-
IC50: 0.0042 mM
additional information
-
inhibition values of peptide inhibitors
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
Acidosis-sensing glutamine pump SNAT2 determines amino acid levels and mammalian target of rapamycin signalling to protein synthesis in L6 muscle cells.
Acidosis
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Acquired Immunodeficiency Syndrome
Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef.
aralkylamine n-acetyltransferase deficiency
Inhibition of the glutamine transporter SNAT1 confers neuroprotection in mice by modulating the mTOR-autophagy system.
aralkylamine n-acetyltransferase deficiency
Prolonged swim-test immobility of serotonin N-acetyltransferase (AANAT)-mutant mice.
Arthus Reaction
Serotonin metabolism in the arthus reaction.
Asthma
N-acetyltransferases as markers for asthma and allergic/atopic disorders.
Astrocytoma
Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas.
Brain Injuries
Up-regulation of miR-325-3p suppresses pineal aralkylamine N-acetyltransferase (Aanat) after neonatal hypoxia-ischemia brain injury in rats.
Brain Neoplasms
Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas.
Breast Neoplasms
Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression.
Breast Neoplasms
Altered Umbilical Cord Blood Nutrient Levels, Placental Cell Turnover and Transporter Expression in Human Term Pregnancies Conceived by Intracytoplasmic Sperm Injection (ICSI).
Breast Neoplasms
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.
Breast Neoplasms
Melatonin pathway genes and breast cancer risk among Chinese women.
Breast Neoplasms
Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study.
Breast Neoplasms
SNAT2 transceptor signalling via mTOR: a role in cell growth and proliferation?
Carcinogenesis
Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression.
Carcinogenesis
O-GlcNAcylation of YY1 stimulates tumorigenesis in colorectal cancer cells by targeting SLC22A15 and AANAT.
Carcinoma, Hepatocellular
Characterization of the amino acid response element within the human sodium-coupled neutral amino acid transporter 2 (SNAT2) System A transporter gene.
Carcinoma, Hepatocellular
Despite Increased ATF4 Binding at the C/EBP-ATF Composite Site following Activation of the Unfolded Protein Response, System A Transporter 2 (SNAT2) Transcription Activity Is Repressed in HepG2 Cells.
Choriocarcinoma
Human placental trophoblasts synthesize melatonin and express its receptors.
Chronobiology Disorders
The flavonoid myricetin reduces nocturnal melatonin levels in the blood through the inhibition of serotonin N-acetyltransferase.
Colorectal Neoplasms
AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors.
Colorectal Neoplasms
Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-??
Colorectal Neoplasms
O-GlcNAcylation of YY1 stimulates tumorigenesis in colorectal cancer cells by targeting SLC22A15 and AANAT.
Endometrial Neoplasms
ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma.
Epilepsy
Modulation of epileptiform activity by glutamine and system A transport in a model of post-traumatic epilepsy.
Glioma
Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas.
Infections
Attacking the Supply Lines: HIV-1 Restricts Alanine Uptake to Prevent T Cell Activation.
Infections
Expression of Melatonin Synthesizing Enzymes in Helicobacter pylori Infected Gastric Mucosa.
Infections
Structure of Mycobacterium smegmatis Eis in complex with paromomycin.
Infections
The Amino Acid-mTORC1 Pathway Mediates APEC TW-XM-Induced Inflammation in bEnd.3 Cells.
Insulin Resistance
Chronic treatment with dexamethasone alters clock gene expression and melatonin synthesis in rat pineal gland at night.
Insulin Resistance
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Intestinal Volvulus
Characterization of the arylalkylamine N-acetyltransferase in Onchocerca volvulus.
Ischemic Attack, Transient
Arylalkylamine N-acetyltransferase (AANAT) is expressed in astrocytes and melatonin treatment maintains AANAT in the gerbil hippocampus induced by transient cerebral ischemia.
Klatskin Tumor
Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.
Liver Cirrhosis
Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis.
Liver Cirrhosis
Prolonged exposure of cholestatic rats to complete dark inhibits biliary hyperplasia and liver fibrosis.
Melanoma
Gender-specific associations between polymorphisms of the circadian gene RORA and cutaneous melanoma susceptibility.
Melanoma
Running for time: circadian rhythms and melanoma.
Melanoma
Serotoninergic and melatoninergic systems are fully expressed in human skin.
Melanoma
Serotoninergic system in hamster skin.
Melanosis
A New Arylalkylamine N-Acetyltransferase in Silkworm (Bombyx mori) Affects Integument Pigmentation.
Melanosis
Mutations of an arylalkylamine-n-acetyl transferase, BM-IAANAT, are responsible for the silkworm melanism mutant.
Neoplasm Metastasis
Increased SNAT1 is a marker of human osteosarcoma and potential therapeutic target.
Neoplasms
AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors.
Neoplasms
Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression.
Neoplasms
Adiponectin Inhibits Nutrient Transporters and Promotes Apoptosis in Human Villous Cytotrophoblasts: Involvement in the Control of Fetal Growth.
Neoplasms
ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma.
Neoplasms
Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Neoplasms
Effect of TNF-alpha on the melatonin synthetic pathway in the rat pineal gland: basis for a 'feedback' of the immune response on circadian timing.
Neoplasms
Histological features and expression of enzymes implicated in melatonin synthesis in pineal parenchymal tumours and in cultured tumoural pineal cells.
Neoplasms
STAT1-NF?B crosstalk triggered by interferon gamma regulates noradrenaline-induced pineal hormonal production.
Neoplasms
The transport of glutamine into mammalian cells.
Neoplasms
TLR4 and CD14 receptors expressed in rat pineal gland trigger NFKB pathway.
Nervous System Diseases
Selective tonicity-induced expression of the neutral amino-acid transporter SNAT2 in oligodendrocytes in rat brain following systemic hypertonicity.
Obesity
Design, synthesis and in vitro evaluation of novel benzo[b]thiophene derivatives as serotonin N-acetyltransferase (AANAT) inhibitors.
Osteosarcoma
Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Osteosarcoma
Increased SNAT1 is a marker of human osteosarcoma and potential therapeutic target.
Paraproteinemias
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.
Peritonitis
Pineal arylalkylamine N-acetyl-transferase (Aanat) gene expression as a target of inflammatory mediators in the chicken.
Pulmonary Edema
Sodium coupled neutral amino acid transporter SNAT2 counteracts cardiogenic pulmonary edema by driving alveolar fluid clearance.
Retinoblastoma
Regulation of AA-NAT and HIOMT gene expression by butyrate and cyclic AMP in Y79 human retinoblastoma cells.
Retinoblastoma
The human serotonin N-acetyltransferase (EC 2.3.1.87) gene (AANAT): structure, chromosomal localization, and tissue expression.
Rett Syndrome
Dysregulation of Glutamine Transporter SNAT1 in Rett Syndrome Microglia: A Mechanism for Mitochondrial Dysfunction and Neurotoxicity.
Sarcopenia
Skeletal muscle: from birth to old age, routes to mechanical and metabolic failure.
Scoliosis
Association study of tryptophan hydroxylase 1 and arylalkylamine N-acetyltransferase polymorphisms with adolescent idiopathic scoliosis in Han Chinese.
Seizures
Differential molecular regulation of glutamate in kindling resistant rats.
Seizures
Modulation of epileptiform activity by glutamine and system A transport in a model of post-traumatic epilepsy.
Sepsis
Sepsis-induced changes in amino acid transporters and leucine signaling via mTOR in skeletal muscle.
Sleep Deprivation
AANAT1 functions in astrocytes to regulate sleep homeostasis.
Sleep Disorders, Circadian Rhythm
Arylalkylamine N-acetyltransferase (AANAT) genotype as a personal trait in melatonin synthesis.
Sleep Disorders, Circadian Rhythm
Significant association of the arylalkylamine N-acetyltransferase ( AA-NAT) gene with delayed sleep phase syndrome.
Sleep Disorders, Circadian Rhythm
The G619A Aa-nat gene polymorphism does not contribute to sleep time variation in the Brazilian population.
Sleep Wake Disorders
Computational Analysis of N-acetyl transferase in Tribolium castaneum.
Sleep Wake Disorders
Crystal structure of the dopamine N-acetyltransferase-acetyl-CoA complex provides insights into the catalytic mechanism.
Squamous Cell Carcinoma of Head and Neck
ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Starvation
Amino acid starvation induces the SNAT2 neutral amino acid transporter by a mechanism that involves eukaryotic initiation factor 2alpha phosphorylation and cap-independent translation.
Starvation
Characterization and Regulation of the Amino Acid Transporter SNAT2 in the Small Intestine of Piglets.
Starvation
Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Starvation
Effects of starvation, re-feeding and timing of food supply on daily rhythm features of gut melatonin in carp (Catla catla).
Starvation
Enhanced small neutral but not branched chain amino acid transport after epigenetic sodium coupled neutral amino acid transporter-2 (SNAT2) cDNA expression in myoblasts.
Starvation
Proteasomal modulation of cellular SNAT2 (SLC38A2) abundance and function by unsaturated fatty acid availability.
Starvation
Specificity of amino acid regulated gene expression: analysis of genes subjected to either complete or single amino acid deprivation.
Starvation
The synthesis of SNAT2 transporters is required for the hypertonic stimulation of system A transport activity.
Stroke
Inhibition of the glutamine transporter SNAT1 confers neuroprotection in mice by modulating the mTOR-autophagy system.
Tuberculosis
Structure of Mycobacterium smegmatis Eis in complex with paromomycin.
Uterine Cervical Neoplasms
Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Vitamin A Deficiency
Regulation of the expression of serotonin N-acetyltransferase gene in Japanese quail (Coturnix japonica): II. Effect of vitamin A deficiency.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00041
acetyl-CoA-tryptamine
Homo sapiens
IC50: 0.00041 mM, GST-AANAT fusion protein
0.00143
bromoacetyltryptamine
Homo sapiens
IC50: 0.00143 mM, GST-AANAT fusion protein
0.002
S 20251
Homo sapiens
IC50: 0.002 mM, GST-AANAT fusion protein
0.005
S 23823
Homo sapiens
IC50: 0.005 mM, GST-AANAT fusion protein
-
0.00072
S 27244
Homo sapiens
IC50: 0.00072 mM, GST-AANAT fusion protein
0.00018
S 27481
Homo sapiens
IC50: 0.00018 mM, GST-AANAT fusion protein
0.0056
S 28036
Homo sapiens
IC50: 0.0056 mM,GST-AANAT fusion protein
0.00039
2-bromo-N-[2-(5-fluoro-1-benzothien-3-yl)ethyl]acetamide
Homo sapiens
-
IC50: 0.00039 mM
0.0014
bromoacetyltryptamine
Homo sapiens
-
IC50: 0.0014 mM
0.16
Melatonin
Homo sapiens
-
IC50 0.16 mM
0.00225
methyl 3-[2-[(bromoacetyl)amino]ethyl]-1-benzothiophene-5-carboxylate
Homo sapiens
-
IC50: 0.00225 mM
0.0087
N-[2-(2-benzyl-5-methoxy-benzofuran-3-yl)ethyl]iodoacetamide
Homo sapiens
-
IC50: 0.0087 mM
0.001
N-[2-(2-phenyl-benzo [b]thiophen-3-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.001 mM
0.0006
N-[2-(3-ethyl-7-methoxy-napht-1-yl)ethyl]iodoacetamide
Homo sapiens
-
IC50: 0.0006 mM
0.00378
N-[2-(5-bromo-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.00378 mM
0.00018
N-[2-(5-chloro-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.00018 mM
0.002
N-[2-(5-ethyl-1-benzothien-3-yl)ethyl]-2-iodoacetamide
Homo sapiens
-
IC50: 0.002 mM
0.00071
N-[2-(5-ethyl-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.00071 mM
0.0056
N-[2-(5-fluoro-1H-indol-3-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.0056 mM
0.00018
N-[2-(5-hydroxy-benzo[b]thiophen-3-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.00018 mM
0.1
N-[2-(7-ethyl-1,2,3,4-tetrahydronapht-1-yl)ethyl]iodooacetamide
Homo sapiens
-
IC50: above 0.1 mM
0.00177
N-[2-(7-ethyl-napht-1-yl)ethyl]-bromoacetamide
Homo sapiens
-
IC50: 0.00177 mM
0.00072
N-[2-(7-hydroxy-naphth-1-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.00072 mM
0.045
N-[2-(7-methoxy-3-(3-trifluoromethylphenyl)-napht-1-yl)ethyl]iodoacetamide
Homo sapiens
-
IC50: 0.045 mM
0.1
N-[2-(7-methoxy-8-propenyl-napht-1-yl)ethyl]-iodoacetamide
Homo sapiens
-
IC50: above 0.1 mM
0.002
N-[2-(7-methoxy-napht-1-yl)ethyl]bromoacetamide
Homo sapiens
-
IC50: 0.002 mM
0.0042
N-[2-(7-propoxy-napht-1-yl)ethyl]iodoacetamide
Homo sapiens
-
IC50: 0.0042 mM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ferry, G.; Loynel, A.; Kucharczyk, N.; Bertin, S.; Rodriguez, M.; Delagrange, P.; Galizzi, J.P.; Jacoby, E.; Volland, J.P.; Lesieur, D.; Renard, P.; Canet, E.; Fauchere, J.L.; Boutin, J.A.
Substrate specificity and inhibition studies of human serotonin N-acetyltransferase
J. Biol. Chem.
275
8794-8805
2000
Ovis aries, Homo sapiens
brenda
Ferry, G.; Ubeaud, C.; Mozo, J.; Pean, C.; Hennig, P.; Rodriguez, M.; Scoul, C.; Bonnaud, A.; Nosjean, O.; Galizzi, J.P.; Delagrange, P.; Renard, P.; Volland, J.P.; Yous, S.; Lesieur, D.; Boutin, J.A.
New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors
Eur. J. Biochem.
271
418-428
2004
Homo sapiens
brenda
Ferry, G.; Ubeaud, C.; Dauly, C.; Mozo, J.; Guillard, S.; Berger, S.; Jimenez, S.; Scoul, C.; Leclerc, G.; Yous, S.; Delagrange, P.; Boutin, J.A.
Purification of the recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and comparison with AANAT from other species
Protein Expr. Purif.
38
84-98
2004
Ovis aries, Homo sapiens (Q16613), Homo sapiens, Rattus norvegicus (Q64666)
brenda
Szewczuk, L.M.; Tarrant, M.K.; Sample, V.; Drury, W.J.; Zhang, J.; Cole, P.A.
Analysis of serotonin N-acetyltransferase regulation in vitro and in live cells using protein semisynthesis
Biochemistry
47
10407-10419
2008
Homo sapiens
brenda
Bloemeke, B.; Golka, K.; Griefahn, B.; Roemer, H.C.
Arylalkylamine N-acetyltransferase (AANAT) genotype as a personal trait in melatonin synthesis
J. Toxicol. Environ. Health
71
874-876
2008
Homo sapiens
brenda
Kang, K.; Lee, K.; Park, S.; Kim, Y.S.; Back, K.
Enhanced production of melatonin by ectopic overexpression of human serotonin N-acetyltransferase plays a role in cold resistance in transgenic rice seedlings
J. Pineal Res.
49
176-182
2010
Homo sapiens
brenda
Prashant, K.; Kumar, H.; Prasad, C.V.
In-silico study of arylalkylamine-nacetyltransferase enzyme to regulate circadian rhythmicity
Bioinformation
9
771-776
2013
Homo sapiens (Q16613), Homo sapiens
brenda
Alkozi, H.; de Lara, M.; Sanchez-Naves, J.; Pintor, J.
TRPV4 stimulation induced melatonin secretion by increasing arylalkymine N-acetyltransferase (AANAT) protein level
Int. J. Mol. Sci.
18
746
2017
Homo sapiens (Q16613), Homo sapiens
brenda
Wadas, B.; Borjigin, J.; Huang, Z.; Oh, J.H.; Hwang, C.S.; Varshavsky, A.
Degradation of serotonin N-acetyltransferase, a circadian regulator, by the N-end rule pathway
J. Biol. Chem.
291
17178-17196
2016
Homo sapiens (Q16613), Homo sapiens, Rattus norvegicus (Q64666)
brenda